AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11871363 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium 40 microg q.i.d.
Number of subjects: 535
Study 9854457 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (2 and 4 micrograms/min)
Number of subjects: 27
Study 9854457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (5 and 10 micrograms/min)
Number of subjects: 27
Study 9854457 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intra-arterial noradrenaline
Number of subjects: 27
Study 9854457 — intervention group
Group type: COMPARATOR
Intervention: Saline infusions
Number of subjects: 27
Study 7608855 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated expression of attitudes during group discussions
Number of subjects: 0
Study 7608855 — intervention group
Group type: EXPERIMENTAL
Intervention: Group members instructed to use each other's arguments
Number of subjects: 0
Study 7608855 — intervention group
Group type: COMPARATOR
Intervention: Group members instructed to avoid using each other's arguments
Number of subjects: 0
Study 2096040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefalozin
Number of subjects: 3137
Study 2096040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 3137
Study 2096040 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 3137
Study 361281 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide 300 microgram/day
Number of subjects: 69
Study 361281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 30831454 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone-extended release formulation
Number of subjects: 602
Study 27609242 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment (open group)
Number of subjects: 0
Study 27609242 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (placebo-controlled group)
Number of subjects: 0
Study 26090572 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 600
Study 26090572 — intervention group
Group type: COMPARATOR
Intervention: qHPV vaccine
Number of subjects: 600
Study 25331879 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for accuracy in evaluating the opposing party
Number of subjects: 2962
Study 25331879 — intervention group
Group type: COMPARATOR
Intervention: Ingroup love attribution
Number of subjects: 2962
Study 25331879 — intervention group
Group type: COMPARATOR
Intervention: Outgroup hate attribution
Number of subjects: 2962
Study 25331879 — intervention group
Group type: COMPARATOR
Intervention: Bias in attribution
Number of subjects: 2962
Study 22982183 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary sphincterotomy (BES)
Number of subjects: 89
Study 22982183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined biliary and pancreatic sphincterotomy (DES)
Number of subjects: 89
Study 22982183 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 89
Study 22982183 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 89
Study 22982183 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SOD
Number of subjects: 89
Study 19216655 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions)
Number of subjects: 127
Study 17990836 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting inhaled anticholinergics
Number of subjects: 0
Study 17990836 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 17990836 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting inhaled anticholinergics, inhaled corticosteroids, possibly long-acting beta2 agonist or mucolytics
Number of subjects: 0
Study 17990836 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting beta2 agonists or combination anticholinergics with a short-acting beta2 agonist
Number of subjects: 0
Study 17990836 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxygen
Number of subjects: 0
Study 16118771 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg)
Number of subjects: 230
Study 16118771 — intervention group
Group type: COMPARATOR
Intervention: Control (chemotherapy alone)
Number of subjects: 230
Study 11990232 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on a readiness model; duration: three months.
Number of subjects: 0
Study 11990232 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 0
Study 9582203 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration of extensor carpi radialis (ECR) tendon
Number of subjects: 0
Study 9582203 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration of extensor carpi ulnaris (ECU) tendon
Number of subjects: 0
Study 9582203 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration of extensor digitorum (ED) tendon
Number of subjects: 0
Study 9582203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of ECR, ECU, and ED tendon vibrations
Number of subjects: 0
Study 7658874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (100 mg followed after 60 min by 200 mg)
Number of subjects: 24
Study 7658874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2541741 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 116
Study 2541741 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 116
Study 2541741 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg
Number of subjects: 116
Study 2541741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 1089090 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana smoking (12 mg delta9‐tetrahydrocannabinol)
Number of subjects: 0
Study 31859127 — intervention group
Group type: EXPERIMENTAL
Intervention: High Saturated Fat (HSF) meal
Number of subjects: 15
Study 31859127 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate meal
Number of subjects: 15
Study 31084482 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtraction CT iodine maps
Number of subjects: 274
Study 31084482 — intervention group
Group type: COMPARATOR
Intervention: CT angiography
Number of subjects: 274
Study 31084482 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy CT
Number of subjects: 274
Study 31084482 — intervention group
Group type: COMPARATOR
Intervention: Subtraction CT
Number of subjects: 274
Study 31084482 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 274
Study 28351427 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS)
Number of subjects: 36
Study 28351427 — intervention group
Group type: COMPARATOR
Intervention: MIRU-VNTR typing
Number of subjects: 36
Study 24285583 — intervention group
Group type: EXPERIMENTAL
Intervention: Connections (correspondence-based interactive recovery-oriented intervention)
Number of subjects: 81
Study 24285583 — intervention group
Group type: COMPARATOR
Intervention: Information (psychoeducational booklet)
Number of subjects: 81
Study 22689129 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of POMx
Number of subjects: 104
Study 22689129 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of POMx
Number of subjects: 104
Study 22689129 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 104
Study 21679641 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal venous arterialization (DVA)
Number of subjects: 36
Study 21679641 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CT)
Number of subjects: 36
Study 18804874 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly water exercise (60 minutes, 1 session per week for 2 years)
Number of subjects: 0
Study 18804874 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly water exercise (60 minutes, 2 sessions per week for 2 years)
Number of subjects: 0
Study 16628277 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.050 U/kg/day)
Number of subjects: 40
Study 16628277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15358335 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain group
Number of subjects: 170
Study 15358335 — intervention group
Group type: COMPARATOR
Intervention: No-drain group
Number of subjects: 170
Study 12712351 — intervention group
Group type: EXPERIMENTAL
Intervention: Running training (runners)
Number of subjects: 10
Study 12712351 — intervention group
Group type: COMPARATOR
Intervention: Non-running (non-runners)
Number of subjects: 10
Study 10370793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 by three-hour infusion on day 1 and gemcitabine 1100 mg/m2 over 30 min on days 1 and 8, repeated every three weeks for six cycles.
Number of subjects: 44
Study 7613276 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 6029
Study 7613276 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants
Number of subjects: 6029
Study 2353093 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tracing-thresholding technique
Number of subjects: 10
Study 93982 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozotocin combined with 5-fluorouracil (5-FU)
Number of subjects: 118
Study 93982 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozotocin combined with cyclophosphamide
Number of subjects: 118
Study 93982 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover therapy with 5-FU alone
Number of subjects: 118
Study 93982 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide alone
Number of subjects: 118
Study 93982 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rates for carcinoids of pulmonary or unknown origin
Number of subjects: 118
Study 93982 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival times by tumor origin
Number of subjects: 118
Study 28273028 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study 28273028 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa plus cytarabine
Number of subjects: 0
Study 25542520 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1185
Study 25542520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1185
Study 25542520 — intervention group
Group type: COMPARATOR
Intervention: Monthly treatment
Number of subjects: 1185
Study 25542520 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfoveal CNV lesions
Number of subjects: 1185
Study 25542520 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from fovea
Number of subjects: 1185
Study 25542520 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominantly classic lesions
Number of subjects: 1185
Study 25542520 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally classic lesions
Number of subjects: 1185
Study 25542520 — intervention group
Group type: EXPERIMENTAL
Intervention: Occult only lesions
Number of subjects: 1185
Study 25542520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eye with GA
Number of subjects: 1185
Study 25542520 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiretinal membrane
Number of subjects: 1185
Study 23669188 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm footbath (40°C water temperature, 20‐min duration)
Number of subjects: 25
Study 23669188 — intervention group
Group type: COMPARATOR
Intervention: Non-bathing
Number of subjects: 25
Study 21842017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 250
Study 21842017 — intervention group
Group type: COMPARATOR
Intervention: Gluma varnish
Number of subjects: 250
Study 19390239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast hydrate plus oral mequitazine
Number of subjects: 0
Study 19390239 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine hydrochloride plus oral mequitazine
Number of subjects: 0
Study 17078057 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone monitoring (TM) + Educational materials (EM)
Number of subjects: 192
Study 17078057 — intervention group
Group type: COMPARATOR
Intervention: Educational materials (EM)
Number of subjects: 192
Study 14742342 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus dose of rocuronium
Number of subjects: 20
Study 14742342 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of rocuronium
Number of subjects: 20
Study 11707740 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 27
Study 9164208 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 150 mg/m2
Number of subjects: 23
Study 9164208 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2
Number of subjects: 23
Study 9164208 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2
Number of subjects: 23
Study 9164208 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m2
Number of subjects: 23
Study 9164208 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m2
Number of subjects: 23
Study 9164208 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 275 mg/m2
Number of subjects: 23
Study 11548230 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonarthrosis patients
Number of subjects: 27
Study 11548230 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonarthrosis patients (unilateral GA)
Number of subjects: 27
Study 11548230 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (women)
Number of subjects: 27
Study 29897822 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 kcal/exercise session, 5 days/wk for 12 wk
Number of subjects: 36
Study 29897822 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 kcal/exercise session, 5 days/wk for 12 wk
Number of subjects: 36
Study 29897822 — intervention group
Group type: COMPARATOR
Intervention: 1,500 kcal/wk ExEE
Number of subjects: 36
Study 29897822 — intervention group
Group type: COMPARATOR
Intervention: 3,000 kcal/wk ExEE
Number of subjects: 36
Study 29897822 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting metabolic rate
Number of subjects: 36
Study 29897822 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 36
Study 29897822 — intervention group
Group type: EXPERIMENTAL
Intervention: Food reinforcement
Number of subjects: 36
Study 29897822 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1
Number of subjects: 36
Study 29897822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylated ghrelin
Number of subjects: 36
Study 27108672 — intervention group
Group type: EXPERIMENTAL
Intervention: lurasidone 40 mg
Number of subjects: 54
Study 27108672 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 25470096 — intervention group
Group type: EXPERIMENTAL
Intervention: RUL brief‐pulse ECT (mean dose = 233.3 mC)
Number of subjects: 73
Study 25470096 — intervention group
Group type: COMPARATOR
Intervention: Algorithm‐based pharmacologic treatment (APT)
Number of subjects: 73
Study 25470096 — intervention group
Group type: EXPERIMENTAL
Intervention: RUL brief‐pulse ECT
Number of subjects: 73
Study 22826463 — intervention group
Group type: EXPERIMENTAL
Intervention: [(14)C]β‐sitosterol administered orally
Number of subjects: 0
Study 22826463 — intervention group
Group type: EXPERIMENTAL
Intervention: [(14)C]β‐sitosterol administered intravenously
Number of subjects: 0
Study 22826463 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary load of β‐sitosterol
Number of subjects: 0
Study 20655180 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10mg intravenously
Number of subjects: 12
Study 20655180 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTP 200 mg
Number of subjects: 12
Study 20655180 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 12
Study 20655180 — intervention group
Group type: COMPARATOR
Intervention: 5-HTP test alone
Number of subjects: 12
Study 20655180 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 12
Study 18240288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-like RF exposure (1 W/kg for 30 min via a 900 MHz GSM mobile phone)
Number of subjects: 30
Study 18240288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RF exposure)
Number of subjects: 30
Study 16754838 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-focused therapy (SFT)
Number of subjects: 88
Study 16754838 — intervention group
Group type: COMPARATOR
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 88
Study 12534636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 50 mg, 100 mg, and 200 mg base as 20-ml gel enemas
Number of subjects: 32
Study 10817324 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicator double gloves
Number of subjects: 566
Study 10817324 — intervention group
Group type: COMPARATOR
Intervention: Single gloves
Number of subjects: 566
Study 8844274 — intervention group
Group type: EXPERIMENTAL
Intervention: MART1
Number of subjects: 16
Study 8844274 — intervention group
Group type: EXPERIMENTAL
Intervention: MART3
Number of subjects: 16
Study 8844274 — intervention group
Group type: COMPARATOR
Intervention: MART5
Number of subjects: 16
Study 8844274 — intervention group
Group type: EXPERIMENTAL
Intervention: MART (all protocols)
Number of subjects: 16
Study 1621138 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (classical tranquilizers)
Number of subjects: 1168
Study 1621138 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 1168
Study 1621138 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 1168
Study 1621138 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical health care providers
Number of subjects: 1168
Study 6363962 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 38
Study 6363962 — intervention group
Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 38
Study 30700475 — intervention group
Group type: COMPARATOR
Intervention: Standard sequential chemoradiotherapy schedule of 55 Gy in 20 fractions over 4 weeks
Number of subjects: 360
Study 30700475 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental radiotherapy schedules (4 separate dose escalation accelerated radiotherapy schedules)
Number of subjects: 360
Study 29033279 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session guided self-help CBT intervention for distressing voices
Number of subjects: 28
Study 29033279 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 28
Study 27362935 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of anti-CD138-IFNα14 and bortezomib
Number of subjects: 0
Study 27362935 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib
Number of subjects: 0
Study 27362935 — intervention group
Group type: COMPARATOR
Intervention: anti-CD138-IFNα14
Number of subjects: 0
Study 27362935 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 25274764 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed blood conservation device
Number of subjects: 284
Study 25274764 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3-way stopcock
Number of subjects: 284
Study 22264575 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of 0 of 4 risk factors
Number of subjects: 4182
Study 22264575 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of 1 of 4 risk factors
Number of subjects: 4182
Study 22264575 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of 2 of 4 risk factors
Number of subjects: 4182
Study 22264575 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of 3 of 4 risk factors
Number of subjects: 4182
Study 22264575 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of 4 of 4 risk factors
Number of subjects: 4182
Study 19418327 — intervention group
Group type: EXPERIMENTAL
Intervention: Kurakkan flour roti
Number of subjects: 0
Study 19418327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice flour roti
Number of subjects: 0
Study 19418327 — intervention group
Group type: EXPERIMENTAL
Intervention: Atta flour roti
Number of subjects: 0
Study 19418327 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled breadfruit
Number of subjects: 0
Study 19418327 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled legumes (mungbean, cowpea, chickpea)
Number of subjects: 0
Study 19418327 — intervention group
Group type: EXPERIMENTAL
Intervention: Kurakkan flour pittu
Number of subjects: 0
Study 19418327 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat flour roti
Number of subjects: 0
Study 19418327 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoppers
Number of subjects: 0
Study 19418327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice flour pittu
Number of subjects: 0
Study 19418327 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat flour pittu
Number of subjects: 0
Study 19418327 — intervention group
Group type: EXPERIMENTAL
Intervention: Olu-milk rice
Number of subjects: 0
Study 17372173 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP levels 1 to 3 mg/L
Number of subjects: 3771
Study 17372173 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP levels >3 mg/L
Number of subjects: 3771
Study 17372173 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated hs-CRP levels
Number of subjects: 3771
Study 16178190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-Twin-block (TB1)
Number of subjects: 56
Study 16178190 — intervention group
Group type: COMPARATOR
Intervention: Unfixed-Twin-block (TB2)
Number of subjects: 56
Study 12480423 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum management group
Number of subjects: 74
Study 12480423 — intervention group
Group type: COMPARATOR
Intervention: BTS management group
Number of subjects: 74
Study 9657513 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 56697 (artemether and benflumetol)
Number of subjects: 260
Study 9657513 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 260
Study 8130019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 30
Study 8130019 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 30
Study 2490928 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration mouthwash (0.16% sodium chloride in an activating system)
Number of subjects: 18